Most guides about clinical trials focus on finding one. How to search. Which criteria to filter by. How to read a ClinicalTrials.gov listing that was clearly written for a regulatory reviewer, not a patient. We built Trial Friend around that problem.
The part almost nobody covers is what comes after you find a trial and say you're interested. That gap between expressing interest and receiving a first dose can stretch for weeks. Forms arrive. People you've never heard of start calling. Silence follows, sometimes for days. The process has a logic to it, and knowing the steps ahead of time makes the slow parts less alarming.
The first phone call comes from someone you've never met
Most patients expect their own doctor to handle enrollment. In practice, the first person who reaches out is usually a clinical research coordinator, sometimes called a CRC. This person is not a physician. CRCs are trained research professionals who work at the trial site, and their job is to figure out whether you might be eligible before anyone books a clinic visit.
The call itself is a pre-screening questionnaire. Expect questions about your diagnosis, current medications, treatment history, and general health. For rare disease trials, the questions get more specific. A parent calling about a Dravet syndrome trial will likely be asked whether the child has a confirmed SCN1A mutation. A patient inquiring about a Pompe disease study may be asked about their current enzyme replacement regimen and most recent GAA enzyme activity levels. These calls typically last 15 to 30 minutes.
If the pre-screen goes well, the next step is an in-person screening visit. If it doesn't, ask the CRC why. The answer might be something fixable, like a lab value that needs retesting in a few weeks. It might also point you toward a different trial at the same site.
The consent form is longer than most patients expect
Before any screening tests begin, you'll receive an informed consent document. A 2021 study in JAMA Network Open analyzed consent forms from 4 major clinical trials and found they averaged 8,333 words, roughly 35 minutes of reading at a normal pace. These documents are written for regulatory compliance. They cover the study's purpose, every known risk, what data will be collected, what happens if you're injured during the trial, and your rights if you decide to withdraw.
Patient comprehension of these documents is lower than most people assume. A systematic review and meta-analysis published in BMC Medical Ethics found that only about 55% of participants could name at least one risk of the trial they'd joined. Roughly half understood the concepts of placebo and randomization. Making the documents longer has not helped. Research published in ESMO Open found that more extensive consent procedures for cancer trials produced no measurable improvement in patient understanding.
Take the document home. You have that right, and no legitimate trial will pressure you to sign the same day. Mark the sections that confuse you. Look for the randomization design, which tells you the probability of receiving the active drug versus a placebo. Find the withdrawal terms, explaining what happens to your care if you decide to leave mid-trial. If an open-label extension section exists, read it carefully. It describes whether you can continue receiving the drug after the main study ends, even before FDA approval. For rare disease patients, the open-label extension question may be the single most important piece of the entire consent form. In a review of FDA and EMA approvals between 2014 and 2018, 12 of 13 drugs that relied on expanded access data for regulatory submission had orphan designation (Polak et al., Orphanet Journal of Rare Diseases, 2020).
Screening is where many patients hear no
Screening is where the research team determines whether you actually meet the study's inclusion and exclusion criteria. These visits run longer than a regular appointment, often 2 to 4 hours, and they can include physical exams, blood draws, ECGs, imaging, and cognitive or functional assessments depending on the condition.
Most screening periods last 1 to 4 weeks. Some labs take time to process. Certain trials require imaging reviewed centrally by a radiologist panel rather than just the local site. If you're being screened for a trial for ALS or Friedreich ataxia, functional assessments may need to be repeated at specific intervals during that window. Travel is part of this equation too. Rare disease trial sites are limited, and if there are only 8 sites running a Duchenne muscular dystrophy trial in the entire United States, the screening visits alone may require flights and hotel stays.
Data from the Tufts Center for the Study of Drug Development puts the average screening failure rate across all therapeutic areas at 36%. In CNS and neurological trials, that figure reaches 57%. The reasons are clinical. Lab values outside protocol-defined limits. Disease progression since the initial inquiry. A medication you're currently taking that falls on the exclusion list. Protocols are written months or years before any individual patient walks through the door, and the criteria reflect statistical design requirements.
The wait between qualifying and starting
Passing screening does not mean you begin treatment the next day. There is usually a gap of days to weeks before your first dose, and a few factors determine how long it lasts.
If the trial uses randomization, you'll be assigned to either the treatment arm or the control arm after screening confirms your eligibility. In a double-blinded study, neither you nor your physician will know which group you're in. For patients with progressive conditions like spinal muscular atrophy or Duchenne muscular dystrophy, time without an active treatment feels genuinely costly. Understanding the randomization ratio before signing the consent form matters. A 1-to-1 design means a 50% chance of receiving the active drug. A 3-to-1 design means 75%.
Some protocols also require a washout period, meaning you must stop your current medication for a set number of days or weeks before receiving the study drug. In cancer trials, washout periods typically run 2 to 6 weeks according to recommendations from the ASCO-Friends of Cancer Research working group. For rare disease patients already on maintenance therapy, this decision deserves a separate conversation with your treating physician, not just the research team. The trial coordinator can tell you how long the washout lasts. Your own doctor can help you think through what that gap might mean for your body.
One email when trials change or decisions land for the conditions you care about. No newsletter, no spam.
What this process is really asking of you
From first phone call to first dose, the clinical trial enrollment process can take anywhere from a few weeks to a few months. That timeline depends on the complexity of the protocol, how quickly labs process, whether a washout period is required, and whether any screening results need repeating. For rare disease patients, add travel coordination and the reality that many trials have only a handful of sites across the country.
The screening and consent infrastructure exists to protect participants, even when it feels slow. Expressing interest in a trial is the beginning of a process, not the end of one. Knowing what each step involves and what questions to raise at each stage puts you in a stronger position to make decisions that fit your life and your disease, not just the protocol's timeline.
If you're looking for trials to consider, Trial Friend's search tools let you filter by condition, phase, and location. If you've already expressed interest and want help thinking through what to expect, our on-page chatbot can walk through the specifics for your condition.